Your browser is no longer supported. Please, upgrade your browser.
Settings
SNSS Sunesis Pharmaceuticals, Inc. daily Stock Chart
SNSS [NASD]
Sunesis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.64 Insider Own0.20% Shs Outstand75.31M Perf Week18.29%
Market Cap64.38M Forward P/E- EPS next Y-0.35 Insider Trans- Shs Float72.35M Perf Month-5.01%
Income-25.20M PEG- EPS next Q-0.10 Inst Own57.60% Short Float1.53% Perf Quarter-36.67%
Sales0.00M P/S- EPS this Y48.30% Inst Trans-0.50% Short Ratio1.01 Perf Half Y21.26%
Book/sh-0.14 P/B- EPS next Y18.60% ROA-116.30% Target Price5.17 Perf Year-64.82%
Cash/sh- P/C- EPS next 5Y- ROE209.00% 52W Range0.20 - 2.60 Perf YTD105.65%
Dividend- P/FCF- EPS past 5Y28.40% ROI267.80% 52W High-67.12% Beta2.80
Dividend %- Quick Ratio2.60 Sales past 5Y-50.50% Gross Margin- 52W Low327.45% ATR0.11
Employees29 Current Ratio2.60 Sales Q/Q- Oper. Margin- RSI (14)55.17 Volatility13.68% 14.88%
OptionableYes Debt/Eq- EPS Q/Q53.20% Profit Margin- Rel Volume1.08 Prev Close0.86
ShortableYes LT Debt/Eq- EarningsAug 07 AMC Payout- Avg Volume1.10M Price0.85
Recom2.00 SMA2022.54% SMA50-3.48% SMA200-12.74% Volume1,187,305 Change-0.59%
Dec-20-18Initiated H.C. Wainwright Neutral
Dec-11-17Upgrade Wells Fargo Market Perform → Outperform
Dec-05-17Downgrade Wells Fargo Outperform → Market Perform
Jul-29-16Upgrade Wells Fargo Market Perform → Outperform
Jul-24-15Downgrade ROTH Capital Buy → Sell $5.50 → $1
Jul-24-15Downgrade Cantor Fitzgerald Buy → Hold
Jun-15-15Reiterated ROTH Capital Buy $4 → $5.50
May-05-15Reiterated ROTH Capital Buy $4.30 → $4
Dec-15-14Upgrade ROTH Capital Neutral → Buy $2.30 → $4.30
Dec-09-14Reiterated ROTH Capital Neutral $1.30 → $2.30
Oct-07-14Downgrade ROTH Capital Buy → Neutral $15 → $1.30
Oct-07-14Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $3
Jun-12-14Initiated UBS Buy $14
Sep-11-12Reiterated Cantor Fitzgerald Buy $6 → $8
May-29-12Upgrade RBC Capital Mkts Sector Perform → Outperform $3 → $5
Apr-13-12Initiated Cantor Fitzgerald Buy $6
Mar-06-12Initiated Canaccord Genuity Buy $4
Oct-11-11Downgrade RBC Capital Mkts Outperform → Sector Perform $4 → $3
Sep-29-11Initiated MLV Capital Buy $3.50
Jul-15-19 02:38PM  How Many Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Shares Do Institutions Own? Simply Wall St.
Jul-11-19 06:17AM  The Daily Biotech Pulse: Neurocrine's Parkinson's Drug Accepted For Review, Sunesis Offering, No Headaches For Biohaven's Migraine Drug Benzinga
12:30AM  Sunesis Announces Pricing of $25 Million Offering of Securities GlobeNewswire
Jul-10-19 04:01PM  Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock GlobeNewswire +16.34%
Jul-08-19 08:30AM  Sunesis Pharmaceuticals Announces Executive Promotions and Provides Clinical Update GlobeNewswire +6.15%
Jun-17-19 08:51AM  Options Traders Expect Huge Moves in Sunesis (SNSS) Stock Zacks -13.36%
Jun-15-19 11:30AM  Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at EHA Annual Meeting GlobeNewswire
Jun-14-19 08:47AM  The Daily Biotech Pulse: Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA Benzinga -5.26%
Jun-08-19 04:09PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts Benzinga
May-17-19 12:24AM  Edited Transcript of SNSS earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
May-08-19 05:52PM  Sunesis: 1Q Earnings Snapshot Associated Press +10.00%
04:05PM  Sunesis Pharmaceuticals Reports First Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
May-01-19 09:26AM  What's in the Cards for Sunesis (SNSS) This Earnings Season? Zacks
07:00AM  Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
Apr-29-19 04:05PM  Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank GlobeNewswire
Apr-04-19 02:35PM  Four Healthcare Stocks Heating Up on Thursday ACCESSWIRE +11.84%
Apr-03-19 07:00AM  Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference GlobeNewswire +14.29%
Mar-28-19 09:53AM  The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals Zacks +17.82%
Mar-27-19 02:47PM  5 Cancer-Fighting Stocks to Boost Portfolio Gains Zacks -15.83%
Mar-22-19 01:38PM  Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS) ACCESSWIRE +30.21%
Mar-15-19 08:21AM  Will Sunesis Pharmaceuticals Continue to Surge Higher? Zacks +5.75%
Mar-14-19 11:32AM  Edited Transcript of SNSS earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents +22.54%
Mar-07-19 04:01PM  Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights GlobeNewswire +36.36%
Mar-04-19 07:00AM  Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Mar-01-19 10:17AM  Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up Zacks
Feb-28-19 07:00AM  Sunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights GlobeNewswire
Feb-15-19 02:25PM  Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock Zacks
10:29AM  Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates Zacks
Jan-18-19 07:49AM  The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug Benzinga -19.82%
Jan-17-19 09:58PM  Sunesis Announces Pricing of $20 Million Offering of Securities GlobeNewswire -13.43%
04:05PM  Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock GlobeNewswire
Jan-02-19 07:00AM  Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies GlobeNewswire +5.85%
Dec-17-18 06:37PM  Edited Transcript of SNSS earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -12.90%
Dec-04-18 07:59AM  The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO Benzinga
Dec-02-18 12:00PM  Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting GlobeNewswire
Nov-29-18 08:06AM  Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals Zacks
Nov-28-18 07:04AM  5 Top-Ranked Rising P/E Stocks to Lure Investors Zacks +7.72%
07:00AM  Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK-Inhibitor Vecabrutinib at Analyst & Investor Event during ASH 2018 GlobeNewswire
Nov-19-18 07:00AM  Sunesis Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference GlobeNewswire -8.13%
Nov-15-18 08:15AM  Report: Developing Opportunities within NeuroMetrix, Sunesis Pharmaceuticals, Siga Technologies, NexPoint Residential Trust, Frequency Electronics, and Horizon Technology Finance Future Expectations, Projections Moving into 2018 GlobeNewswire +8.70%
Nov-05-18 06:28PM  Sunesis: 3Q Earnings Snapshot Associated Press
04:05PM  Sunesis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Nov-01-18 09:17AM  Sunesis Pharmaceuticals Announces Presentations at 60th American Society of Hematology Annual Meeting GlobeNewswire -7.14%
Oct-29-18 07:00AM  Sunesis Pharmaceuticals to Host Conference Call on November 5th to Discuss Third Quarter 2018 Financial Results and Recent Highlights GlobeNewswire -5.63%
Sep-26-18 07:00AM  Sunesis Pharmaceuticals to Present at the 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-12-18 11:56AM  Should You Worry About The Sunesis Pharmaceuticals Incs (NASDAQ:SNSS) Shareholder Register? Simply Wall St.
Sep-06-18 02:02PM  Edited Transcript of SNSS earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-30-18 07:00AM  Sunesis Pharmaceuticals to Present at the Wells Fargo Securities 2018 Healthcare Conference GlobeNewswire +5.88%
Aug-07-18 07:13PM  Sunesis: 2Q Earnings Snapshot Associated Press
04:05PM  Sunesis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Jul-31-18 07:00AM  Sunesis Pharmaceuticals to Host Conference Call on August 7th to Discuss Second Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Jul-09-18 07:00AM  Sunesis Pharmaceuticals Strengthens Senior Management Team GlobeNewswire +13.74%
Jun-25-18 04:10PM  Sunesis Pharmaceuticals Enters into $15.5 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC GlobeNewswire
Jun-18-18 07:00AM  Sunesis Pharmaceuticals Announces Presentations at the EHA Annual Meeting GlobeNewswire
Jun-15-18 09:13AM  5 Biotech Stocks Under $10 Worthy of Investors' Attention Zacks
May-14-18 11:42AM  Edited Transcript of SNSS earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-08-18 04:46PM  Sunesis: 1Q Earnings Snapshot Associated Press -5.71%
04:00PM  Sunesis Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
May-01-18 04:05PM  Sunesis Pharmaceuticals to Host Conference Call on May 8th to Discuss First Quarter 2018 Financial Results and Recent Highlights GlobeNewswire
Apr-09-18 08:56AM  Are Options Traders Betting on a Big Move in Sunesis Pharmaceuticals (SNSS) Stock? Zacks
Mar-14-18 04:05PM  Sunesis Pharmaceuticals to Present at Upcoming Investor Conferences GlobeNewswire -15.67%
Mar-13-18 07:00AM  Sunesis Pharmaceuticals Announces Cancellation of Presentation and Webcast at Cowen & Company 38th Annual Health Care Conference GlobeNewswire
Mar-09-18 04:11PM  Edited Transcript of SNSS earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents -42.39%
Mar-08-18 06:54PM  Sunesis reports 4Q loss Associated Press
04:05PM  Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights GlobeNewswire
01:00PM  Sunesis Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
10:25AM  Sunesis Pharmaceuticals Q4 Earnings Preview Benzinga
Mar-07-18 06:11AM  Are Earnings Prospects Improving For Loss-Making Sunesis Pharmaceuticals Incs (NASDAQ:SNSS)? Simply Wall St.
Mar-06-18 07:00AM  Sunesis Pharmaceuticals to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 07:00AM  Sunesis Pharmaceuticals to Host Conference Call on March 8th to Discuss Fourth Quarter and Full-Year 2017 Financial Results and Recent Highlights GlobeNewswire
Feb-07-18 04:05PM  Sunesis Pharmaceuticals Appoints Industry Veteran H. Ward Wolff to the Board of Directors GlobeNewswire
Dec-05-17 07:00AM  Sunesis Pharmaceuticals to Provide Program Update for Non-Covalent BTK Inhibitor SNS-062 at Analyst & Investor Event during ASH 2017 GlobeNewswire -11.48%
Dec-04-17 04:05PM  Sunesis Pharmaceuticals Announces Change in Leadership GlobeNewswire
Nov-30-17 04:25PM  Edited Transcript of SNSS earnings conference call or presentation 2-Nov-17 6:00pm GMT Thomson Reuters StreetEvents
07:00AM  Sunesis Pharmaceuticals Appoints William Quinn as Chief Financial Officer and Senior Vice President, Finance and Corporate Development GlobeNewswire
Nov-16-17 08:00AM  Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS) ACCESSWIRE
Nov-02-17 09:47AM  Sunesis reports 3Q loss Associated Press +10.88%
07:00AM  Sunesis Pharmaceuticals Reports Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Oct-27-17 07:00AM  Sunesis to Host Conference Call on November 2nd to Discuss Third Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Oct-25-17 08:54AM  Sunesis Announces Pricing of $20 Million Offering of Securities GlobeNewswire +11.89%
Oct-24-17 04:05PM  Sunesis Announces Proposed Public Offering of Common Stock, Preferred Stock and Warrants GlobeNewswire
Oct-03-17 09:36AM  Zacks.com featured highlights include MINDBODY, TearLab, Sunesis Pharmaceuticals, Children's Place, Franklin Electric Zacks
Oct-02-17 06:21AM  Step Beyond Bargain Hunting: 5 Stocks With Rising P/E Zacks
Aug-31-17 07:00AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
Aug-13-17 09:25AM  Edited Transcript of SNSS earnings conference call or presentation 27-Jul-17 6:00pm GMT Thomson Reuters StreetEvents
Jul-27-17 02:53PM  Sunesis reports 2Q loss Associated Press
07:00AM  Sunesis Pharmaceuticals Reports Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Jul-24-17 07:00AM  Sunesis to Host Conference Call on July 27th to Discuss Second Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Jul-18-17 04:05PM  Sunesis Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-062 in Adults with Chronic Lymphocytic Leukemia and other B-Cell Malignancies GlobeNewswire
Jun-26-17 07:00AM  Sunesis Pharmaceuticals Added to Russell Microcap® Index GlobeNewswire
Jun-23-17 07:00AM  Sunesis Pharmaceuticals Announces Presentation of Updated Results from Washington University-Sponsored Phase 1/Cohort Expansion Trial of Vosaroxin Plus Azacitidine in Patients with MDS at the EHA Annual Meeting GlobeNewswire
May-19-17 06:18PM  IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm Business Wire
08:45AM  The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug Marketwired
May-15-17 07:08PM  Lifshitz & Miller LLP Announces Investigation of Anadarko Petroleum Corporation, DryShips Inc., ImmunoCellular Therapeutics, Ltd., KBR, Inc., Sunesis Pharmaceuticals, Inc., Sunrun Inc. and Vince Holding Corp. PR Newswire
May-12-17 11:05PM  Edited Transcript of SNSS earnings conference call or presentation 8-May-17 6:00pm GMT Thomson Reuters StreetEvents
May-11-17 05:32PM  ETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 11, 2017 Capital Cube
May-10-17 10:25AM  Sunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 Capital Cube
May-08-17 09:00AM  Investor Network: Sunesis Pharmaceuticals, Inc. to Host Earnings Call Accesswire
07:04AM  Sunesis reports 1Q loss Associated Press
07:00AM  Sunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights GlobeNewswire
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aisling Capital IV, LP10% OwnerJul 15Buy0.602,500,0001,500,00010,100,000Jul 15 04:15 PM
Quinn William P.CFO,Sr.V.P. Finance, Corp.Dev.Dec 10Buy0.4740,00018,80052,000Dec 12 04:57 PM